Intensity Therapeutics Inc banner

Intrinsic Value

The intrinsic value of Intensity Therapeutics Inc (INTS) under the Base Case is 16.5804 USD per share. Compared with the current market price of 2.7878 USD, the stock appears Undervalued by 83% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

INTS Intrinsic Value
$16.5804
Undervaluation 83%
Intrinsic Value
Price $2.7878
Alert me when INTS is below its intrinsic value
Today $13.2643 · Already reached, the price is 79.0% below it

INTS is valued in line with its history. A discount of this size has been typical over the past 3 years.

Alternatives to INTS

Fundamental Analysis

What Intensity Therapeutics Does

Biotechnology Health Care

Intensity Therapeutics is a clinical-stage biotechnology company that develops cancer treatments designed to be injected directly into a tumor. Its approach uses the tumor itself to help trigger an immune response, with the goal of shrinking the injected tumor and helping the body attack cancer elsewhere. The company’s lead work is focused on solid tumors, where doctors and cancer centers would be the users if the therapies reach market.

Headquarters
United States of America US
Employees
3
IPO date
Jun 30, 2023
Read the full company overview
View Company Overview
Financials
Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Continue INTS Research

Decided on Intensity Therapeutics? Get an email when INTS reaches the price you’d buy at. Free with an account.

What is the Intrinsic Value of one INTS stock?

The intrinsic value for Intensity Therapeutics Inc (INTS) under the Base Case is 16.5804 USD.

Is INTS stock undervalued or overvalued?

Compared with the current market price of 2.7878 USD, the stock appears Undervalued by 83% .

How reliable are our estimates? See how past valuations played out
Back to Top